Genentech Updates Results From Phase III MARIANNE Trial In Advanced HER2-Positive Breast Cancer Patients

Genentech Updates Results From Phase III MARIANNE Trial In Advanced HER2-Positive Breast Cancer Patients
shutterstock_84410140Genentech, a member of the Roche Group, recently announced the results from their Phase III MARIANNE study. MARIANNE is an international, multicenter, randomized, three-arm study comprising 1,095 patients with advanced HER2-positive breast cancer. Patients enrolled had either inoperable locally advanced disease that had worsened during or returned after previous treatment, or metastases. The study assessed the feasibility of three different regimens targetting HER2 in people with previously untreated (first-line) advanced HER2-positive breast cancer. Patients enrolled in the study received one of the three composites: Kadcyla (ado-trastuzumab emtansine) plus Perjeta (pertuzumab), Kadcyla alone, and Herceptin (trastuzumab) plus either docetaxel or paclitaxel chemotherapy. An Independent Review Committee assessed progression-free survival (PFS), the study’s primary endpoint. Overall survival, response rate and the incidence of adverse events were all secondary endpoints. Variations in these endpoints were assessed in each of the Kadcyla-containing treatment arms compared to the Herceptin plus chemotherapy arm, and also between the two Ka
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.